How gender and sex influence clinical trial recruitment in Alzheimer's disease: Findings from Fundació ACE Barcelona Alzheimer Treatment and Research Center

Background FDA has made great efforts to promote inclusion of women in clinical trials. The aim is to protect specific biological gender and sex issues and encourage drug developers to consider specific clinical outcomes and drug‐safety profiles in terms of gender and sex. Alzheimer’s disease (AD) affects predominantly women, who double men in the number of patients diagnosed with dementia. Therefore, we explored gender and sex bias in the...